Timothy Kerwin, MD (@KerwinXRT) header
Timothy Kerwin, MD (@KerwinXRT) profile picture

Radiation Oncologist, NCH, PRMC. Sports trivia enthusiast and #girldad #radonc

Naples, FL
Joined December 2020
Photo by Timothy Kerwin, MD (@KerwinXRT)Photo by Timothy Kerwin, MD (@KerwinXRT)Photo by Timothy Kerwin, MD (@KerwinXRT)Photo by Timothy Kerwin, MD (@KerwinXRT)Photo by Timothy Kerwin, MD (@KerwinXRT)Photo by Timothy Kerwin, MD (@KerwinXRT)
Timothy Kerwin, MD retweeted
New ASTRO Clinical Practice Guideline: Radiation Therapy for Bladder Cancer ASTRO has issued its first clinical guideline on radiation therapy for bladder cancer. Recommendations support trimodal therapy as a curative alternative to bladder removal for select patients and define radiotherapy’s role after surgery and in advanced disease. Published in Practical Radiation Oncology. Read the news release: bit.ly/4yAKPkr
1
26
56
3,133
Timothy Kerwin, MD retweeted
Phase III Trial | Will this become the new TNT standard for high-risk rectal cancer? The TNTCRT trial tested an intensified long-course TNT strategy with uninterrupted CAPOX + long-course RT versus conventional long-course chemoradiotherapy in 458 patients with high-risk stage II/III rectal cancer. Key results: ✅ 3-year DFS: 74.8% vs 66.0% • HR 0.67 (95% CI 0.49-0.93) • P=0.016 ✅ Metastasis-free survival: • 77.7% vs 67.6% • HR 0.66 ✅ Pathologic CR: • 26.4% vs 9.8% • P<0.001 ⚖️ Trade-off: • Higher grade ≥3 toxicity during neoadjuvant therapy 27.6% vs 8.6% • But overall severe toxicity across the entire treatment course was similar 28.0% vs 24.3% • Major postoperative complications were also comparable. Clinical takeaway 🩺 This is one of the strongest phase III datasets supporting doublet chemotherapy integrated throughout long-course radiotherapy in high-risk LARC, delivering meaningful improvements in DFS, MFS, and pCR with acceptable overall safety. Will this approach replace conventional long-course CRT in your practice, or do you still prefer other TNT strategies such as RAPIDO/PRODIGE-23/STELLAR? #RectalCancer #GIOncology #ASCO #OncoAlert @ASCO @JCO_ASCO @oncoalert
5
63
126
10,141
Adjuvant Radiotherapy Enhances Control of High-Risk Bladder Cancer Read about the study 🔗 zurl.co/PtQvY The study, published in the @JCO_ASCO indicates potential benefits for disease-free and overall survival, though these were not statistically significant. #RadOnc #RadOncNews #RadiationOncology #CancerCare #BladderCancer
1
5
286
Timothy Kerwin, MD retweeted
Overall Survival Among Patients With Hepatocellular Carcinoma Treated With External Beam Radiation Therapy: Individual Patient Data Outcomes From a Multinational Cohort. Read the full article. bit.ly/3RQHtKi
2
4
1,168
Local Salvage Therapy Alone for Local Recurrence of Prostate Cancer After Radiotherapy: A Systematic Review and Meta-Analysis jamanetwork.com/journals/jam… Local salvage therapies for radiorecurrent prostate cancer show reasonable outcomes in selected patients wishing to avoid androgen deprivation therapy. Across 31 studies (4525 patients), 2- and 5-year ADT-free survival were 76.8% and 55.2%, while metastasis-free survival reached 90.4% and 75.2%. Severe adverse events varied by modality (2–14%). Despite selection bias and limited randomized data, these approaches☢️offer a viable alternative with acceptable toxicity and meaningful disease control. #ProstateCancer @miszczyk_marcin @AmarUKishan @ArjunSNathan @BarbaraJereczek @DrShariat @dr_rajwa @GiulioFrancoli1 @GMarra_MD @paolo_gontero @PetePocharapong @OncoAlert 🚨 @Silke_Gillessen @AOmlin @weoncologists
1
21
1
47
2,983
Timothy Kerwin, MD retweeted
PROTEUS and STAMPEDE both support ARPI intensification in high-risk M0 prostate cancer, but across different designs and local treatments. The real advance is not “which wins?” It is “which patient, which path?” #ASCO26 @DrChoueiri @TiansterZhang @CathyEngMD @montypal @tompowles1 @brian_rini @cdanicas @GlopesMd @PGrivasMDPhD @nataliagandur @yekeduz_emre @neerajaiims @ASCO @ONCOassist @OpenMedicineHQ @MedwatchKate @scserendipity1 @CParkMD @urotoday @OncLive @crisbergerot @urologysummit @SuyogCancer @Larvol @IMG_Oncologists @piet_ost @DrSpratticus @GGiannarini @declangmurphy @NehaVapiwala @Prof_Nick_James @AttardLab @Silke_Gillessen @APCCC_Lugano
4
48
3
96
14,397
Timothy Kerwin, MD retweeted
Adaptive radiotherapy involves modifying treatment plans to account for changes in anatomical geometry that are not adequately mitigated with changes in alignment. Online adaptive radiotherapy capitalizes on advances in image guidance, real-time tumor tracking, and the enhanced speed of multiple steps in radiotherapy planning and delivery workflows (seen in image). Learn more in the Review Article “Effects of Radiotherapy in Normal Tissue” by @DeborahCitrin, MD, and Robert D. Timmerman, MD (@BobTimmermanMD), from the National Cancer Institute and @UTSWMedCenter: nejm.org/doi/full/10.1056/NE…
1
58
3
137
15,646
Timothy Kerwin, MD retweeted
A new review summarizes advances in radiotherapy that reduce injury to normal tissue, including improvements in the precision of imaging and delivery, and outlines strategies to prevent and manage treatment-related side effects. Read the Review Article “Effects of Radiotherapy in Normal Tissue” by @DeborahCitrin, MD, and Robert D. Timmerman, MD (@BobTimmermanMD), from the National Cancer Institute and @UTSWMedCenter: nejm.org/doi/full/10.1056/NE…
42
135
11,782
Timothy Kerwin, MD retweeted
Stereotactic radiation outperforms hippocampal-avoidance whole brain radiation for 5–20 brain metastases. It better reduces symptoms and protects daily function. @JAMA_current @BrighamWomens @AyalAizer @OncoAlert
34
70
4,134
Timothy Kerwin, MD retweeted
In localized radiorecurrent #ProstateCancer, salvage focal therapy provided similar 10-year survival outcomes as radical prostatectomy but resulted in substantially fewer perioperative complications. ja.ma/4rbkdTR
4
27
7
75
27,667
Timothy Kerwin, MD retweeted
🎵 Randomized trial (N=300) of telehealth-delivered Music Therapy vs CBT among cancer survivors with anxiety shows that music therapy was non-inferior and led to durable anxiety reduction. The core of the intervention: collaborative songwriting. Fantastic. ascopubs.org/doi/10.1200/JCO…
4
10
5
51
29,985
Timothy Kerwin, MD retweeted
Standard esophagectomy after neoadjuvant chemoradiation may provide greater long-term survival and quality-of-life benefits than active surveillance for most patients with esophageal cancer. ja.ma/4sPlBNb
2
11
2
41
9,222
Timothy Kerwin, MD retweeted
Tumor Treating Fields Therapy After Stereotactic Radiosurgery for Brain Metastases From Non-Small Cell Lung Cancer: Final Results of the Phase 3 METIS Study - International Journal of Radiation Oncology, Biology, Physics redjournal.org/article/S0360…
4
6
709
Timothy Kerwin, MD retweeted
☢️New meta-analysis in JAMA Network Open: 🎯Stereotactic body radiotherapy (SBRT) alone for oligometastatic cancer achieved 70% systemic therapy-free survival at 1-2 years, highest in renal (87%) and prostate cancer (78%). 🎯Low toxicity rates suggest SBRT may safely defer chemotherapy in selected patients. 10.1001/jamanetworkopen.2025.49685 @OncoAlert @DrYukselUrun #MedX #Cancer #Oncology @JAMANetworkOpen
7
98
3
230
19,222
Timothy Kerwin, MD retweeted
Proton versus photon radiotherapy for patients with oropharyngeal cancer in the USA: a multicentre, randomised, open-label, non-inferiority phase 3 trial hubs.li/Q03-8-Bq0
2
22
6,783
Timothy Kerwin, MD retweeted
Healthcare innovation 🎯🩺 Southwest Florida Proton has delivered its first proton therapy treatment, officially becoming the first cancer center on Florida’s west coast to offer this highly advanced and precise form of radiation therapy. Learn more: prioritymarketing.com/southw…
1
1
61
Timothy Kerwin, MD retweeted
Nice to see this article on de-escalation: Optimal Duration of Androgen Deprivation Therapy With Definitive Radiotherapy for Localized Prostate Cancer: A Meta-Analysis | Reproductive Health | JAMA Oncology | JAMA Network jamanetwork.com/journals/jam…
1
3
6
424